New Drug Cuts Seizures 91% in Kids With Rare Epilepsy

Children with Dravet syndrome finally have hope for a treatment that doesn't just manage symptoms but attacks the disease at its source.

Dravet syndrome is a rare and severe childhood epilepsy that causes frequent seizures, developmental delays, coordination problems, and a heartbreaking 50% risk of sudden death. Current treatments can reduce some seizures but do nothing for the developmental challenges families face every day.

Now a new drug called zorevunersen is changing everything. In an early trial of 81 children ages 2 to 18, those who received the highest dose saw their seizures drop between 59% and 91% after 20 months of treatment.

The drug works by fixing the genetic mutation that causes Dravet syndrome. Most people have two copies of a gene called SCN1A, which helps brain cells communicate properly. In Dravet patients, one copy doesn't work. Zorevunersen boosts the working copy to compensate for the broken one.

Dr. Helen Cross, who led the study at University College London, calls it "one of the first disease-modifying trials for early-onset complex epilepsy." The treatment is given through a lumbar puncture every four months, and the effects last between doses.

Beyond seizure reduction, families reported improvements in their children's overall quality of life. The drug was safe, with only mild side effects like headaches or temporary protein increases in spinal fluid.

The study, published in The New England Journal of Medicine, was small and didn't include a placebo group. But researchers are already testing 170 more children in a larger trial to confirm these promising results.

Why This Inspires

For families living with Dravet syndrome, every day brings fear of the next seizure and grief over missed developmental milestones. This drug offers something they've never had before: the possibility of addressing the disease itself, not just its symptoms.

The treatment represents a breakthrough in precision medicine, where doctors can target specific genetic problems instead of just managing their consequences. It's a reminder that some of medicine's most complex challenges can be solved when scientists focus on understanding diseases at their deepest level.

Most importantly, 75 of the original 81 children in the trial chose to continue treatment, following their progress for three years. That kind of commitment from families speaks volumes about the real-world difference this drug is making in their lives.

Science is turning a devastating diagnosis into a manageable condition, one genetic fix at a time.